About zymeworks inc - ZYME
Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.
ZYME At a Glance
Zymeworks, Inc.
108 Patriot Drive
Middletown, Delaware 19709
| Phone | 1-302-274-8744 | Revenue | 76.30M | |
| Industry | Pharmaceuticals: Major | Net Income | -122,695,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 0.384% | |
| Fiscal Year-end | 12 / 2025 | Employees | 286 | |
| View SEC Filings |
ZYME Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.552 |
| Price to Book Ratio | 3.005 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -8.314 |
| Enterprise Value to Sales | 11.836 |
| Total Debt to Enterprise Value | 0.02 |
ZYME Efficiency
| Revenue/Employee | 266,797.203 |
| Income Per Employee | -429,003.497 |
| Receivables Turnover | 1.367 |
| Total Asset Turnover | 0.146 |
ZYME Liquidity
| Current Ratio | 3.403 |
| Quick Ratio | 3.403 |
| Cash Ratio | 2.557 |
ZYME Profitability
| Gross Margin | 85.331 |
| Operating Margin | -157.034 |
| Pretax Margin | -152.824 |
| Net Margin | -160.798 |
| Return on Assets | -23.505 |
| Return on Equity | -30.537 |
| Return on Total Capital | -34.342 |
| Return on Invested Capital | -29.151 |
ZYME Capital Structure
| Total Debt to Total Equity | 5.463 |
| Total Debt to Total Capital | 5.18 |
| Total Debt to Total Assets | 3.996 |
| Long-Term Debt to Equity | 4.654 |
| Long-Term Debt to Total Capital | 4.413 |